VYNE Therapeutics (VYNE)
Market Price (7/28/2026): $28.88 | Market Cap: $24.7 MilSector: Health Care | Industry: Biotechnology
VYNE Therapeutics (VYNE)
Market Price (7/28/2026): $28.88Market Cap: $24.7 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -102% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Dermatological Therapeutics, and Targeted Therapies. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5368% Stock price has recently run up significantly6M Rtn6 month market price return is 4846%, 12M Rtn12 month market price return is 1856% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -25%, Rev Chg QQuarterly Revenue Change % is -57% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 445% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5670%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5670% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 5892% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -92% High stock price volatilityVol 12M is 3663% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% Key risksVYNE key risks include [1] the failure of its lead vitiligo drug in a late-stage trial and an FDA clinical hold on its psoriasis candidate due to toxicity concerns, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -102% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Dermatological Therapeutics, and Targeted Therapies. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -24 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -5368% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 4846%, 12M Rtn12 month market price return is 1856% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -25%, Rev Chg QQuarterly Revenue Change % is -57% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 445% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -5670%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -5670% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 5892% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -92% |
| High stock price volatilityVol 12M is 3663% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 22% |
| Key risksVYNE key risks include [1] the failure of its lead vitiligo drug in a late-stage trial and an FDA clinical hold on its psoriasis candidate due to toxicity concerns, Show more. |
Qualitative Assessment
AI Analysis | Feedback
VYNE Therapeutics (VYNE) stock has gained about 4680% since 3/31/2026 because of the following key factors:
1. Merger Completion with Yarrow Bioscience, Inc.
VYNE Therapeutics completed its reverse merger with Yarrow Bioscience, Inc. on July 27, 2026. This strategic transaction transformed VYNE into a clinical-stage biotechnology company focused on autoimmune thyroid diseases. The combined entity now operates as Yarrow Bioscience, Inc., with its shares expected to commence trading on the Nasdaq Capital Market under the ticker symbol "YARW" on July 28, 2026. This merger was a pivotal event that reshaped the company's future and pipeline.
2. Significant Special Cash Dividend Distribution.
In connection with the merger, VYNE Therapeutics declared and distributed a substantial special cash dividend totaling $17.3 million, or approximately $0.40242 per share, to its stockholders and warrant holders of record as of July 22, 2026. The dividend payment occurred on July 23, 2026. This significant cash distribution to shareholders likely contributed to investor interest and the stock's upward trend.
Show more
VYNE Therapeutics (VYNE) stock has gained about 4680% since 3/31/2026 because of the following key factors:
1. Merger Completion with Yarrow Bioscience, Inc.
VYNE Therapeutics completed its reverse merger with Yarrow Bioscience, Inc. on July 27, 2026. This strategic transaction transformed VYNE into a clinical-stage biotechnology company focused on autoimmune thyroid diseases. The combined entity now operates as Yarrow Bioscience, Inc., with its shares expected to commence trading on the Nasdaq Capital Market under the ticker symbol "YARW" on July 28, 2026. This merger was a pivotal event that reshaped the company's future and pipeline.
2. Significant Special Cash Dividend Distribution.
In connection with the merger, VYNE Therapeutics declared and distributed a substantial special cash dividend totaling $17.3 million, or approximately $0.40242 per share, to its stockholders and warrant holders of record as of July 22, 2026. The dividend payment occurred on July 23, 2026. This significant cash distribution to shareholders likely contributed to investor interest and the stock's upward trend.
3. Implementation of a Reverse Stock Split.
VYNE Therapeutics executed a 1-for-50 reverse stock split on July 24, 2026, which was previously approved by its stockholders. This action drastically reduced the number of outstanding shares from approximately 33.4 million to about 0.7 million. While a reverse split itself does not alter market capitalization, it typically results in a higher per-share price, which can enhance the stock's appeal to a broader investor base and potentially improve its listing compliance.
4. Advancement of Yarrow Bioscience's Lead Program, YB-101.
The combined company's strategic focus is on advancing Yarrow Bioscience's lead product candidate, YB-101. This potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody for Graves' disease (GD) and thyroid eye disease (TED) has begun dosing patients in a Phase 2a/2b trial. Furthermore, YB-101 has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), highlighting its potential to address unmet medical needs and providing a positive outlook for the newly merged entity.
Show less
Stock Movement Drivers
Fundamental Drivers
The 4679.9% change in VYNE stock from 3/31/2026 to 7/27/2026 was primarily driven by a 5891.5% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.60 | 28.56 | 4679.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -20.4% |
| P/S Multiple | 0.9 | 53.8 | 5891.5% |
| Shares Outstanding (Mil) | 1 | 1 | 0.2% |
| Cumulative Contribution | 4679.9% |
Market Drivers
3/31/2026 to 7/27/2026| Return | Correlation | |
|---|---|---|
| VYNE | 4679.9% | |
| Market (SPY) | 13.6% | -2.2% |
| Sector (XLV) | 11.5% | 4.0% |
Fundamental Drivers
The 4823.3% change in VYNE stock from 12/31/2025 to 7/27/2026 was primarily driven by a 5578.0% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.58 | 28.56 | 4823.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -13.4% |
| P/S Multiple | 0.9 | 53.8 | 5578.0% |
| Shares Outstanding (Mil) | 1 | 1 | 0.1% |
| Cumulative Contribution | 4823.3% |
Market Drivers
12/31/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| VYNE | 4823.3% | |
| Market (SPY) | 8.7% | -0.4% |
| Sector (XLV) | 6.0% | 4.0% |
Fundamental Drivers
The 1630.9% change in VYNE stock from 6/30/2025 to 7/27/2026 was primarily driven by a 2211.7% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.65 | 28.56 | 1630.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -25.0% |
| P/S Multiple | 2.3 | 53.8 | 2211.7% |
| Shares Outstanding (Mil) | 1 | 1 | -0.2% |
| Cumulative Contribution | 1630.9% |
Market Drivers
6/30/2025 to 7/27/2026| Return | Correlation | |
|---|---|---|
| VYNE | 1630.9% | |
| Market (SPY) | 20.6% | -0.3% |
| Sector (XLV) | 22.8% | 3.1% |
Fundamental Drivers
The 596.6% change in VYNE stock from 6/30/2023 to 7/27/2026 was primarily driven by a 7923.6% change in the company's P/S Multiple.| (LTM values as of) | 6302023 | 7272026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.10 | 28.56 | 596.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 14.1% |
| P/S Multiple | 0.7 | 53.8 | 7923.6% |
| Shares Outstanding (Mil) | 0 | 1 | -92.4% |
| Cumulative Contribution | 596.6% |
Market Drivers
6/30/2023 to 7/27/2026| Return | Correlation | |
|---|---|---|
| VYNE | 596.6% | |
| Market (SPY) | 72.6% | 0.5% |
| Sector (XLV) | 28.9% | 2.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| VYNE Return | -84% | -85% | -14% | 44% | -83% | 31% | -99% |
| Peers Return | 25% | 6% | -16% | 78% | 45% | 9% | 212% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 97% |
Monthly Win Rates [3] | |||||||
| VYNE Win Rate | 8% | 25% | 42% | 58% | 50% | 57% | |
| Peers Win Rate | 60% | 62% | 45% | 57% | 62% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| VYNE Max Drawdown | -93% | -90% | -74% | -48% | -93% | -9% | |
| Peers Max Drawdown | -29% | -27% | -42% | -26% | -25% | -22% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: INCY, ARQT, ABBV, PFE, LLY.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/27/2026 (YTD)
How Low Can It Go
| Event | VYNE | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -15.5% | -7.8% |
| % Gain to Breakeven | 18.4% | 8.5% |
| Time to Breakeven | 27 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.3% | -9.5% |
| % Gain to Breakeven | 64.8% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -37.7% | -6.7% |
| % Gain to Breakeven | 60.6% | 7.1% |
| Time to Breakeven | 37 days | 31 days |
In The Past
VYNE Therapeutics's stock fell -15.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 18.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | VYNE | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -39.3% | -9.5% |
| % Gain to Breakeven | 64.8% | 10.5% |
| Time to Breakeven | 19 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -37.7% | -6.7% |
| % Gain to Breakeven | 60.6% | 7.1% |
| Time to Breakeven | 37 days | 31 days |
In The Past
VYNE Therapeutics's stock fell -15.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 18.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About VYNE Therapeutics (VYNE)
VYNE Therapeutics Inc. is a pharmaceutical company primarily focused on developing novel treatments for immuno-inflammatory conditions. The company's strategy revolves around advancing a pipeline of investigational therapies designed to address a variety of diseases characterized by immune system dysfunction and inflammation.
The company's most advanced product candidate is FCD105, a topical combination foam that has successfully completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris, targeting a significant patient population suffering from this common skin condition. VYNE also has FMX114, a combination therapy in earlier-stage development for mild-to-moderate atopic dermatitis, addressing another prevalent inflammatory skin disease.
Further expanding its therapeutic reach, VYNE is developing VYN201 and VYN202, which are bromodomain and extra-terminal (BET) inhibitors. These compounds represent a promising class of drugs aimed at treating a broader spectrum of immuno-inflammatory diseases, including other skin conditions, by modulating gene expression involved in inflammatory processes.
AI Analysis | Feedback
Here are 1-3 brief analogies for VYNE Therapeutics:
- It's like an early-stage Regeneron Pharmaceuticals, but specializing in developing new treatments for skin and other immuno-inflammatory conditions.
- Think of it as a developing biotech similar to Viking Therapeutics, but with a focus on innovative drugs for inflammatory skin diseases rather than metabolic disorders.
AI Analysis | Feedback
- FCD105: A topical combination foam developed for the treatment of moderate-to-severe acne vulgaris.
- FMX114: A combination of tofacitinib being developed for the treatment of mild-to-moderate atopic dermatitis.
- VYN201: A bromodomain and extra-terminal (BET) inhibitor aimed at various immuno-inflammatory diseases, including skin conditions.
- VYN202: A BET inhibitor compound designed to be selective for bromodomain 2.
AI Analysis | Feedback
VYNE Therapeutics Inc. is a pharmaceutical company that develops and commercializes prescription medications. As such, its primary customers are not individuals, but rather companies within the pharmaceutical supply chain that facilitate the distribution of these drugs to pharmacies, hospitals, and ultimately, patients.
Therefore, VYNE Therapeutics sells primarily to other companies. Its major customers would typically include:
- Pharmaceutical Wholesalers and Distributors: These companies purchase prescription drugs directly from manufacturers and then distribute them to a vast network of retail pharmacies, hospitals, clinics, and other healthcare providers. The largest pharmaceutical wholesalers in the United States, and likely VYNE's major customers, include:
- McKesson Corporation (Symbol: MCK)
- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
AI Analysis | Feedback
AI Analysis | Feedback
David Domzalski, President and Chief Executive Officer
Mr. Domzalski has served as President and Chief Executive Officer and a member of the board of VYNE Therapeutics since March 2020. Prior to joining VYNE, he was Chief Executive Officer and a member of the board of Foamix Pharmaceuticals Ltd. from July 2017, having been with Foamix since April 2014 and previously serving as President. He brings over 25 years of industry experience, including roles as Vice President, Sales and Marketing, at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President, Sales and Marketing, at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College.
Tyler Zeronda, Chief Financial Officer, Principal Accounting Officer and Treasurer
Mr. Zeronda was appointed Chief Financial Officer and Treasurer of VYNE Therapeutics Inc. on March 14, 2022. He had been serving as the company's Interim Chief Financial Officer and Treasurer since June 2021. Before his interim appointment, Mr. Zeronda served as Vice President of Finance for the company.
Dr. Iain Stuart, Chief Scientific Officer
Dr. Stuart serves as the Chief Scientific Officer of VYNE Therapeutics. He has been with the company since February 2020.
Mutya Harsch, General Counsel, Chief Legal Officer and Company Secretary
Ms. Harsch holds the titles of General Counsel, Chief Legal Officer, and Company Secretary at VYNE Therapeutics. She has served in these roles since February 2020.
AI Analysis | Feedback
The key risks for VYNE Therapeutics (VYNE) are primarily associated with the inherent challenges of drug development, regulatory approval, and market commercialization in the highly competitive pharmaceutical industry.
-
Failure to Obtain Regulatory Approval and Successfully Commercialize Lead Product Candidate: VYNE's most advanced product candidate, FCD105 for moderate-to-severe acne vulgaris, has completed Phase III clinical trials. A significant risk is the potential failure to receive regulatory approval (e.g., from the FDA) despite positive trial results, or encountering delays in the approval process. Even if approved, there is a risk of failing to successfully commercialize FCD105 due to challenges in market access, pricing, reimbursement, physician adoption, or competitive pressures, which would severely impact the company's revenue generation and viability.
-
Clinical Trial Failures for Early-Stage Pipeline Candidates: The company's future growth and value depend heavily on the successful development of its earlier-stage pipeline, including FMX114 for atopic dermatitis (in Phase IIa preclinical trial) and VYN201/VYN202 (BET inhibitors for various immuno-inflammatory diseases). These candidates face significant risks of failure at any stage of clinical development (Phase I, II, or III) due to lack of efficacy, unacceptable safety profiles, or other unforeseen issues. Such failures would lead to substantial financial losses and could significantly diminish the company's long-term prospects.
-
Intense Competition in Immuno-Inflammatory Disease Markets: VYNE operates in highly competitive therapeutic areas, particularly acne vulgaris and atopic dermatitis. There are numerous approved treatments and other companies developing new therapies, including those with potentially superior efficacy, safety, or convenience. This intense competition could limit the market share, pricing power, and commercial success of VYNE's product candidates, even if they receive regulatory approval. Competitors may also have greater financial, marketing, and R&D resources, posing a significant challenge to VYNE's ability to establish and maintain a competitive position.
AI Analysis | Feedback
AI Analysis | Feedback
VYNE Therapeutics Inc. develops therapeutics for immuno-inflammatory conditions, with key product candidates targeting acne vulgaris and atopic dermatitis.
FCD105 for Moderate-to-Severe Acne Vulgaris
The global market for acne treatment, which includes moderate-to-severe cases, was valued at approximately USD 12.19 billion in 2025 and is projected to reach USD 19.55 billion by 2034, growing at a CAGR of 5.40% from 2026 to 2034. More specifically for the moderate-to-severe acne treatment market, it is projected to grow from USD 1,449.5 million in 2025 to USD 2,670.3 million by 2035 globally. In the United States, the acne treatment market size was valued at USD 5.00 billion in 2022 and is projected to grow to USD 7.27 billion by 2030, exhibiting a CAGR of 4.7%.
FMX114 for Mild-to-Moderate Atopic Dermatitis
The global atopic dermatitis drugs market is projected to be USD 14.4 billion in 2026 and is expected to grow to USD 34.4 billion by 2035, expanding at a CAGR of 10.1%. The overall global atopic dermatitis market size is also projected to be USD 21.15 billion in 2026 and is forecast to grow to USD 33.29 billion by 2031. For the United States, the atopic dermatitis drugs market generated a revenue of USD 6,405.7 million in 2024 and is expected to reach USD 9,991.8 million by 2030. Topical formulations held the largest share of the atopic dermatitis market, accounting for 61.20% in 2025, with topical being the first-line treatment for mild to moderate atopic dermatitis.
AI Analysis | Feedback
For VYNE Therapeutics (symbol: VYNE), the expected drivers of future revenue growth over the next 2-3 years are primarily linked to its recently announced merger with Yarrow Bioscience and the advancement of Yarrow's pipeline. As of December 17, 2025, VYNE Therapeutics entered into a merger agreement with Yarrow Bioscience, with the combined entity expected to operate under the name Yarrow Bioscience, Inc. and focus on Yarrow's pipeline.
-
Commercialization of YB-101 for Graves' Disease and Thyroid Eye Disease: The lead asset of Yarrow Bioscience, YB-101, an antibody for Graves' disease and thyroid eye disease, is anticipated to be the primary driver of future revenue for the combined company. The post-merger strategy indicates a shift in focus to Yarrow's pipeline.
-
Advancement of Yarrow Bioscience's Broader Pipeline: The merger agreement highlights that Yarrow's pipeline will become the primary business of the combined entity. This suggests that other undisclosed or early-stage assets from Yarrow Bioscience could contribute to future revenue growth as they progress through development and potential commercialization.
-
Strategic Partnerships and Licensing Agreements: As a clinical-stage biopharmaceutical company, the combined entity may pursue strategic partnerships or licensing agreements for Yarrow's pipeline assets. These collaborations could provide upfront payments, milestone payments, and future royalties, contributing to revenue growth and potentially accelerating the development and market access of its therapies.
AI Analysis | Feedback
Share Issuance
- In January 2021, VYNE Therapeutics completed a registered direct offering of 21,097,046 shares of common stock, generating gross proceeds of approximately $50.0 million.
- In November 2023, the company executed a private placement financing (PIPE) that raised gross proceeds of $88 million.
- This PIPE involved the sale of 10,652,543 shares of common stock and pre-funded warrants to purchase an additional 28,614,437 shares.
Inbound Investments
- In November 2023, VYNE Therapeutics secured an $88 million private placement led by Access Biotechnology, with participation from other institutional investors.
Outbound Investments
- VYNE Therapeutics has not made any investments or acquisitions.
Capital Expenditures
- The company reported $0 in capital expenditures, with operating cash flow primarily consumed by research and development activities.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| VYNE Therapeutics Earnings Notes | 12/16/2025 | |
| Can VYNE Therapeutics Stock Hold Up When Markets Turn? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 73.71 |
| Mkt Cap | 82.0 |
| Rev LTM | 34,090 |
| Op Inc LTM | 8,479 |
| FCF LTM | 5,452 |
| FCF 3Y Avg | 1,284 |
| CFO LTM | 6,750 |
| CFO 3Y Avg | 6,032 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 15.5% |
| Rev Chg 3Y Avg | 11.9% |
| Rev Chg Q | 16.7% |
| QoQ Delta Rev Chg LTM | 3.5% |
| Op Inc Chg LTM | 67.3% |
| Op Inc Chg 3Y Avg | 63.5% |
| Op Mgn LTM | 25.8% |
| Op Mgn 3Y Avg | 17.2% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | 23.6% |
| CFO/Rev 3Y Avg | 19.0% |
| FCF/Rev LTM | 14.7% |
| FCF/Rev 3Y Avg | 7.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Development of differentiated therapies to treat inflammatory and immune-mediated conditions of high | 1 | 1 | 0 | ||
| Royalty revenues | 0 | 1 | |||
| Total | 1 | 1 | 0 | 0 | 1 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development of differentiated therapies to treat inflammatory and immune-mediated conditions of high | -30 | -44 | -29 |
| Total | -30 | -44 | -29 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Development of differentiated therapies to treat inflammatory and immune-mediated conditions of high | -26 | -40 | -28 |
| Total | -26 | -40 | -28 |
| $ Mil | 2019 |
|---|---|
| Single segment | 79 |
| Total | 79 |
Price Behavior
| Market Price | $28.56 | |
| Market Cap ($ Bil) | 1.2 | |
| First Trading Date | 01/25/2018 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $1.23 | $0.69 |
| DMA Trend | up | up |
| Distance from DMA | 2,227.1% | 4,028.3% |
| 3M | 1YR | |
| Volatility | 7,698.9% | 3,715.1% |
| Downside Capture | -2366.06 | -386.72 |
| Upside Capture | 48.35 | 49.47 |
| Correlation (SPY) | 2.9% | 5.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.04 | 0.04 | 0.24 | 0.27 | 0.63 | 0.95 |
| Up Beta | -0.73 | -0.63 | 0.46 | 0.26 | 1.26 | 0.80 |
| Down Beta | 1.12 | 0.99 | 0.91 | 1.02 | 0.03 | 1.11 |
| Up Capture | -41% | -3% | 13% | 14% | 36% | 29% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 25 | 37 | 73 | 127 | 345 |
| Down Capture | 11% | -24% | -43% | -22% | 145% | 109% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 9 | 15 | 25 | 51 | 122 | 381 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VYNE | |
|---|---|---|---|---|
| VYNE | -43.5% | 101.5% | 0.16 | - |
| Sector ETF (XLV) | 22.0% | 15.7% | 1.07 | 9.6% |
| Equity (SPY) | 17.6% | 12.7% | 1.00 | 5.1% |
| Gold (GLD) | 20.8% | 28.1% | 0.66 | 9.5% |
| Commodities (DBC) | 29.6% | 19.5% | 1.21 | 6.8% |
| Real Estate (VNQ) | 13.9% | 14.1% | 0.69 | 17.1% |
| Bitcoin (BTCUSD) | -46.0% | 43.0% | -1.31 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VYNE | |
|---|---|---|---|---|
| VYNE | -56.7% | 105.1% | -0.28 | - |
| Sector ETF (XLV) | 6.8% | 15.0% | 0.27 | 12.2% |
| Equity (SPY) | 13.2% | 17.1% | 0.59 | 16.7% |
| Gold (GLD) | 17.2% | 18.4% | 0.75 | 5.0% |
| Commodities (DBC) | 9.7% | 19.5% | 0.38 | 1.5% |
| Real Estate (VNQ) | 3.3% | 18.9% | 0.07 | 17.1% |
| Bitcoin (BTCUSD) | 15.8% | 53.5% | 0.47 | 6.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with VYNE | |
|---|---|---|---|---|
| VYNE | -54.7% | 102.7% | -0.36 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | 13.5% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 17.5% |
| Gold (GLD) | 11.4% | 16.1% | 0.58 | 3.8% |
| Commodities (DBC) | 6.9% | 18.0% | 0.30 | 6.2% |
| Real Estate (VNQ) | 5.2% | 20.7% | 0.21 | 15.3% |
| Bitcoin (BTCUSD) | 58.0% | 66.2% | 0.98 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/20/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 4.6% | 4.3% | 10.6% |
| 8/14/2025 | 0.7% | -5.9% | -10.6% |
| 5/8/2025 | -5.1% | -8.0% | -27.0% |
| 3/6/2025 | -2.5% | -22.6% | -30.1% |
| 11/7/2024 | 0.8% | -7.0% | -14.4% |
| 8/14/2024 | 1.2% | 7.0% | 4.7% |
| 5/9/2024 | -2.6% | 1.5% | -17.3% |
| 2/29/2024 | -4.3% | 0.9% | 31.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 5 |
| # Negative | 11 | 12 | 16 |
| Median Positive | 4.2% | 7.0% | 10.6% |
| Median Negative | -5.1% | -11.9% | -16.3% |
| Max Positive | 9.3% | 30.8% | 31.8% |
| Max Negative | -31.1% | -47.1% | -45.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | 4.6% | 4.3% | 10.6% |
| 8/14/2025 | 0.7% | -5.9% | -10.6% |
| 5/8/2025 | -5.1% | -8.0% | -27.0% |
| 3/6/2025 | -2.5% | -22.6% | -30.1% |
| 11/7/2024 | 0.8% | -7.0% | -14.4% |
| 8/14/2024 | 1.2% | 7.0% | 4.7% |
| 5/9/2024 | -2.6% | 1.5% | -17.3% |
| 2/29/2024 | -4.3% | 0.9% | 31.8% |
| 11/13/2023 | -0.9% | 11.4% | -26.5% |
| 8/14/2023 | 9.3% | -13.7% | -25.8% |
| 3/9/2023 | -13.0% | -15.7% | -10.0% |
| 11/10/2022 | 8.0% | -10.2% | -29.3% |
| 8/12/2022 | 3.8% | 9.1% | -6.6% |
| 5/12/2022 | 7.2% | 7.6% | 26.6% |
| 3/17/2022 | 6.1% | 30.8% | -7.9% |
| 11/10/2021 | -3.7% | -9.6% | 1.5% |
| 8/12/2021 | -31.1% | -47.1% | -45.7% |
| 5/6/2021 | -21.2% | -22.6% | -15.3% |
| 3/4/2021 | -9.7% | -6.1% | -6.5% |
| 11/5/2020 | 2.9% | 2.3% | -1.2% |
| 8/6/2020 | -13.8% | -13.8% | -25.2% |
| SUMMARY STATS | |||
| # Positive | 10 | 9 | 5 |
| # Negative | 11 | 12 | 16 |
| Median Positive | 4.2% | 7.0% | 10.6% |
| Median Negative | -5.1% | -11.9% | -16.3% |
| Max Positive | 9.3% | 30.8% | 31.8% |
| Max Negative | -31.1% | -47.1% | -45.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/11/2023 | 10-Q |
| 12/31/2022 | 03/14/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/12/2022 | 10-Q |
| 12/31/2021 | 03/17/2022 | 10-K |
| 09/30/2021 | 11/10/2021 | 10-Q |
| 06/30/2021 | 08/12/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 03/04/2021 | 10-K |
| 09/30/2020 | 11/05/2020 | 10-Q |
| 06/30/2020 | 08/06/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/03/2020 | 10-K |
| 09/30/2019 | 10/31/2019 | 10-Q |
| 06/30/2019 | 08/01/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.